Phase 3, double blinded, placebo controlled study of the effects of 12 weeks DPP-IV inhibitor treatment on secretion and action of the incretin hormones in patients with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2014
At a glance
- Drugs Sitagliptin (Primary) ; CD26 antigen inhibitors
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 06 Nov 2012 Investigational drug identified as Sitagliptin as reported by European Clinical Trials Database.
- 05 Jan 2007 New trial record.